“I founded Gaia Health with a vision for healthcare that doesn’t pose a compromise between health outcomes and quality of life as we receive care. I believe that taking a female-centered approach to designing drug products can transform the experience of taking medicine, and in doing so create massive improvements in how we manage disease. I’m a materials scientist, a fierce optimist, and a connector.”

Emily came up with the idea for Gaia while living in Kyoto, where the culture of simplicity and attention to detail resonated strongly with her vision for healthcare.

Prior to founding Gaia, Emily studied Materials Science and Engineering at Stanford where she worked on novel medical devices and 3D printed sensors.

Dr. Kevin Cyr is a physician and life sciences investor with a focus on cardiovascular health and prevention. He obtained his medical degree from Stanford University with a concentration in Cardiovascular Bioengineering and trained at Cedars-Sinai Medical Center. He has written academic publications that have been featured in the Journal of the American College of Cardiology and the American Heart Association. As an investor, Kevin has worked with the Global Bioaccessfund, a life sciences venture fund and has helped make investments in leading pharmaceutical and medtech companies.

Alexandra “Lexi” Burdon serves as Chief of Staff for Gaia and joins us after earning a B.S. from Stanford University in Science, Technology, and Society. She brings an understanding of systematic transformation thanks to her background studying gendered innovations and medical anthropology, and leverages her network and experiences working with faculty and students from Stanford School of Medicine throughout her undergraduate career.

Aakaash Margam is one of our team members at Gaia and has been responsible for leading our financial projections and market analysis. He is currently a senior at the University of Pennsylvania concentrating in Finance at the Wharton School of Business with a dual degree in Psychology in the College of Arts & Sciences. After graduation, he will be working as an investment banking analyst at Perella Weinberg Partners within their Healthcare group.

Scientific Advisor

Professor of Pharmaceutical Sciences at University of Pittsburgh and Magee Women’s Research Institute

Pharmaceutical Advisor

Former COO of two Phase 2/3 publicly traded companies and CEO of a private venture backed Phase 2 company.

Clinical Advisor

Professor emeritus of OBGYN at Stanford

Clinical Advisor

Professor emeritus of Endocrinology at Stanford

Strategic Advisor

Partner at Index Ventures